MCRB — Seres Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $165.55m
- $120.17m
Annual cashflow statement for Seres Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -89.1 | -65.6 | -250 | -114 | 0.136 |
| Depreciation | |||||
| Non-Cash Items | 12.1 | 24.8 | 33.1 | 49.1 | -88.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -23.2 | 41.5 | -18.4 | -59 | -65.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -93.6 | 6.69 | -229 | -117 | -149 |
| Capital Expenditures | -0.591 | -9.57 | -9.82 | -7.97 | -0.38 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -158 | 73.7 | 92.2 | 18.6 | 143 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -159 | 64.1 | 82.4 | 10.6 | 142 |
| Financing Cash Flow Items | 19.9 | 0 | — | — | 13.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 303 | 1.18 | 130 | 71.7 | -90.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 50.9 | 72 | -16.8 | -35.1 | -96.7 |